Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates

Gomaa, Mohamed S., Lim, Andrew S. T., Lau, Sze C. W., Watts, Ann-Marie, Illingworth, N. A., Bridgens, C. E., Veal, G. J., Redfern, C. P. F., Brancale, Andrea ORCID: https://orcid.org/0000-0002-9728-3419, Armstrong, J. L. and Simons, Claire ORCID: https://orcid.org/0000-0002-9487-1100 2012. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates. Bioorganic & Medicinal Chemistry 20 (20) , pp. 6080-6088. 10.1016/j.bmc.2012.08.044

Full text not available from this repository.

Abstract

The role of all-trans-retinoic acid (ATRA) in the development and maintenance of many epithelial and neural tissues has raised great interest in the potential of ATRA and related compounds (retinoids) as pharmacological agents, particularly for the treatment of cancer, skin, neurodegenerative and autoimmune diseases. The use of ATRA or prodrugs as pharmacological agents is limited by a short half-life in vivo resulting from the activity of specific ATRA hydroxylases, CYP26 enzymes, induced by ATRA in liver and target tissues. For this reason retinoic acid metabolism blocking agents (RAMBAs) have been developed for treating cancer and a wide range of other diseases. The synthesis, CYP26A1 inhibitory activity and molecular modeling studies of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates are presented. From this series of compounds clear SAR can be derived for 4-substitution of the phenyl ring with electron-donating groups more favourable for inhibitory activity. Both the methylenedioxyphenyl imidazole (17, IC50 = 8 nM) and triazole (18, IC50 = 6.7 nM) derivatives were potent inhibitors with additional binding interactions between the methylenedioxy moiety and the CYP26 active site likely to be the main factor. The 6-bromo-3-pyridine imidazole 15 (IC50 = 5.7 nM) was the most active from this series compared with the standards liarozole (IC50 = 540 nM) and R116010 (IC50 = 10 nM).

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	CYP26A1; Methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoate derivatives; IC50 enzyme inhibition; MCF-7; Molecular modeling
Publisher:	Elsevier
ISSN:	0968-0896
Last Modified:	05 Jan 2024 05:53
URI:	https://orca.cardiff.ac.uk/id/eprint/40767

Citation Data

Cited 12 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item